{
    "xml": "<topic id=\"PHP5362\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/capecitabine\" basename=\"capecitabine\" title=\"CAPECITABINE\">\n<title>CAPECITABINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_923\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/capecitabine\">Capecitabine</xref>\n</p>\n<data name=\"vtmid\">108761006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_699299946\" title=\"Antimetabolites\">Antimetabolites</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP43353\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/capecitabine\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Capecitabine is metabolised to fluorouracil.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43173\" outputclass=\"indicationsAndDose\" rev=\"1.23\" parent=\"/drugs/capecitabine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Stage III colon cancer, adjuvant following surgery (monotherapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1.25&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Stage III colon cancer, adjuvant following surgery (combination therapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.8&#8211;1&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic colcorectal cancer (monotherapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1.25&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic colorectal cancer (combination therapy)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.8&#8211;1&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Advanced gastric cancer (first-line treatment in combination with a platinum based regimen)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.8&#8211;1&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625&#8239;mg/m<sup>2</sup> twice daily given continuously, adjust dose according to tolerability&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Locally advanced or metastatic breast cancer (second-line treatment as monotherapy after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated)</p>\n<p outputclass=\"therapeuticIndication\">Locally advanced or metastatic breast cancer (second-line treatment, in combination with docetaxel, where previous therapy included an anthracycline)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1.25&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43380\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/capecitabine\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43411\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/capecitabine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Dihydropyrimidine dehydrogenase deficiency</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43585\" outputclass=\"cautions\" rev=\"1.9\" parent=\"/drugs/capecitabine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diabetes mellitus</ph>; <ph outputclass=\"caution\">diarrhoea or dehydration&#8212;consult product literature for guidance on dose modification and treatment interruption</ph>; <ph outputclass=\"caution\">electrolyte disturbances</ph>; <ph outputclass=\"caution\">history of angina pectoris</ph>; <ph outputclass=\"caution\">history of arrhythmias</ph>; <ph outputclass=\"caution\">history of significant cardiovascular disease</ph>; <ph outputclass=\"caution\">nervous system disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43142\" outputclass=\"interactions\" rev=\"1.23\" parent=\"/drugs/capecitabine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (capecitabine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42999\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/capecitabine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For further information on side-effects, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43488\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/capecitabine\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency).</p>\n<p>Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.</p>\n<p>No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43119\" outputclass=\"pregnancy\" parent=\"/drugs/capecitabine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic in <i>animal</i> studies).</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43665\" outputclass=\"breastFeeding\" parent=\"/drugs/capecitabine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43210\" outputclass=\"hepaticImpairment\" parent=\"/drugs/capecitabine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises monitor liver function in mild to moderate impairment&#8212;consult product literature for guidance on treatment interruption; avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43056\" outputclass=\"renalImpairment\" parent=\"/drugs/capecitabine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce starting dose of 1.25&#8239;g/m<sup>2</sup> to 75% if creatinine clearance 30&#8211;50&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if creatinine clearance less than 30&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42772\" outputclass=\"monitoringRequirements\" parent=\"/drugs/capecitabine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">Severe skin reactions</p>\n<p>Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)&#8212;permanently discontinue treatment immediately if symptoms occur.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hand-foot syndrome</p>\n<p>Monitor for symptoms of hand-foot syndrome&#8212;interrupt treatment if significant syndrome occurs and refer to product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor plasma-calcium concentration.</p>\n<p>Monitor for eye disorders (including keratitis and corneal disorders).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP42552\" outputclass=\"nationalFunding\" rev=\"1.20\" parent=\"/drugs/capecitabine\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA61</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Capecitabine and tegafur with uracil for metastatic colorectal cancer (May 2003)</p>\r\n<p>Capecitabine or tegafur with uracil [now discontinued] (in combination with folinic acid) is an option for the first-line treatment of metastatic colorectal cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA61\">www.nice.org.uk/TA61</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA100</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes&#8217; C) colon cancer (April 2006)</p>\r\n<p>Capecitabine alone <i>or</i> oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes&#8217; C) colon cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA100\">www.nice.org.uk/TA100</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA191</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Capecitabine for the treatment of advanced gastric cancer (July 2010)</p>\r\n<p>Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA191\">www.nice.org.uk/TA191</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA212</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p>\r\n<p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <b>not</b> recommended for the treatment of metastatic colorectal cancer.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA212\">www.nice.org.uk/TA212</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA263</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</p>\r\n<p>Bevacizumab in combinations with capecitabine is <b>not</b> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA263\">www.nice.org.uk/TA263</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5362-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/capecitabine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76147\" title=\"Tablet\" namespace=\"/drugs/capecitabine/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78591\" namespace=\"/treatment-summaries/hormones-malignant-disease\" title=\"Hormones, malignant disease\" count=\"1\" rel=\"backlink\">Hormones, malignant disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_923\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antimetabolites/capecitabine\" title=\"Capecitabine\" count=\"1\" rel=\"link\">Capecitabine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76147\" namespace=\"/drugs/capecitabine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP5362",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/capecitabine",
    "basename": "capecitabine",
    "title": "CAPECITABINE",
    "interactants": [
        {
            "id": "bnf_int_923",
            "label": "Capecitabine"
        }
    ],
    "vtmid": "108761006",
    "drugClassification": [
        "Antimetabolites"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Capecitabine is metabolised to fluorouracil.",
                "html": "<p>Capecitabine is metabolised to fluorouracil.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Stage III colon cancer, adjuvant following surgery (monotherapy)",
                        "html": "Stage III colon cancer, adjuvant following surgery (monotherapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.",
                        "html": "<p>1.25&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Stage III colon cancer, adjuvant following surgery (combination therapy)",
                        "html": "Stage III colon cancer, adjuvant following surgery (combination therapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "0.8&#8211;1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.",
                        "html": "<p>0.8&#8211;1&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Metastatic colcorectal cancer (monotherapy)",
                        "html": "Metastatic colcorectal cancer (monotherapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.",
                        "html": "<p>1.25&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Metastatic colorectal cancer (combination therapy)",
                        "html": "Metastatic colorectal cancer (combination therapy)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "0.8&#8211;1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.",
                        "html": "<p>0.8&#8211;1&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Advanced gastric cancer (first-line treatment in combination with a platinum based regimen)",
                        "html": "Advanced gastric cancer (first-line treatment in combination with a platinum based regimen)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "0.8&#8211;1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625 mg/m2 twice daily given continuously, adjust dose according to tolerability&#8212;consult product literature.",
                        "html": "<p>0.8&#8211;1&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625&#8239;mg/m<sup>2</sup> twice daily given continuously, adjust dose according to tolerability&#8212;consult product literature.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Locally advanced or metastatic breast cancer (second-line treatment as monotherapy after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated)",
                        "html": "Locally advanced or metastatic breast cancer (second-line treatment as monotherapy after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated)"
                    },
                    {
                        "textContent": "Locally advanced or metastatic breast cancer (second-line treatment, in combination with docetaxel, where previous therapy included an anthracycline)",
                        "html": "Locally advanced or metastatic breast cancer (second-line treatment, in combination with docetaxel, where previous therapy included an anthracycline)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.",
                        "html": "<p>1.25&#8239;g/m<sup>2</sup> twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Dihydropyrimidine dehydrogenase deficiency",
                "html": "Dihydropyrimidine dehydrogenase deficiency"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diabetes mellitus",
                "html": "Diabetes mellitus"
            },
            {
                "type": "cautions",
                "textContent": "diarrhoea or dehydration&#8212;consult product literature for guidance on dose modification and treatment interruption",
                "html": "diarrhoea or dehydration&#8212;consult product literature for guidance on dose modification and treatment interruption"
            },
            {
                "type": "cautions",
                "textContent": "electrolyte disturbances",
                "html": "electrolyte disturbances"
            },
            {
                "type": "cautions",
                "textContent": "history of angina pectoris",
                "html": "history of angina pectoris"
            },
            {
                "type": "cautions",
                "textContent": "history of arrhythmias",
                "html": "history of arrhythmias"
            },
            {
                "type": "cautions",
                "textContent": "history of significant cardiovascular disease",
                "html": "history of significant cardiovascular disease"
            },
            {
                "type": "cautions",
                "textContent": "nervous system disease",
                "html": "nervous system disease"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (capecitabine).",
                "html": "<p>Appendix 1 (capecitabine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "For further information on side-effects, consult product literature.",
                "html": "<p>For further information on side-effects, consult product literature.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency).\n\nPretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.\n\nNo increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency).</p><p>Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.</p><p>No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic in animal studies).\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises monitor liver function in mild to moderate impairment&#8212;consult product literature for guidance on treatment interruption; avoid in severe impairment.",
                "html": "<p>Manufacturer advises monitor liver function in mild to moderate impairment&#8212;consult product literature for guidance on treatment interruption; avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce starting dose of 1.25 g/m2 to 75% if creatinine clearance 30&#8211;50 mL/minute.",
                "html": "<p>Reduce starting dose of 1.25&#8239;g/m<sup>2</sup> to 75% if creatinine clearance 30&#8211;50&#8239;mL/minute.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if creatinine clearance less than 30 mL/minute.",
                "html": "<p>Avoid if creatinine clearance less than 30&#8239;mL/minute.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "Severe skin reactions",
                "textContent": "Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)&#8212;permanently discontinue treatment immediately if symptoms occur.",
                "html": "<p>Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)&#8212;permanently discontinue treatment immediately if symptoms occur.</p>"
            },
            {
                "type": "patientParameters",
                "title": "Hand-foot syndrome",
                "textContent": "Monitor for symptoms of hand-foot syndrome&#8212;interrupt treatment if significant syndrome occurs and refer to product literature.",
                "html": "<p>Monitor for symptoms of hand-foot syndrome&#8212;interrupt treatment if significant syndrome occurs and refer to product literature.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor plasma-calcium concentration.\n\nMonitor for eye disorders (including keratitis and corneal disorders).",
                "html": "<p>Monitor plasma-calcium concentration.</p><p>Monitor for eye disorders (including keratitis and corneal disorders).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA61",
                        "label": "www.nice.org.uk/TA61"
                    }
                ],
                "fundingIdentifier": "NICE TA61",
                "textContent": "Capecitabine and tegafur with uracil for metastatic colorectal cancer (May 2003) Capecitabine or tegafur with uracil [now discontinued] (in combination with folinic acid) is an option for the first-line treatment of metastatic colorectal cancer.\n\nwww.nice.org.uk/TA61",
                "html": "<p outputclass=\"title\">Capecitabine and tegafur with uracil for metastatic colorectal cancer (May 2003)</p> <p>Capecitabine or tegafur with uracil [now discontinued] (in combination with folinic acid) is an option for the first-line treatment of metastatic colorectal cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA61\">www.nice.org.uk/TA61</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA100",
                        "label": "www.nice.org.uk/TA100"
                    }
                ],
                "fundingIdentifier": "NICE TA100",
                "textContent": "Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes&#8217; C) colon cancer (April 2006) Capecitabine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes&#8217; C) colon cancer.\n\nwww.nice.org.uk/TA100",
                "html": "<p outputclass=\"title\">Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes&#8217; C) colon cancer (April 2006)</p> <p>Capecitabine alone <i>or</i> oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes&#8217; C) colon cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA100\">www.nice.org.uk/TA100</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA191",
                        "label": "www.nice.org.uk/TA191"
                    }
                ],
                "fundingIdentifier": "NICE TA191",
                "textContent": "Capecitabine for the treatment of advanced gastric cancer (July 2010) Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer.\n\nwww.nice.org.uk/TA191",
                "html": "<p outputclass=\"title\">Capecitabine for the treatment of advanced gastric cancer (July 2010)</p> <p>Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA191\">www.nice.org.uk/TA191</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA212",
                        "label": "www.nice.org.uk/TA212"
                    }
                ],
                "fundingIdentifier": "NICE TA212",
                "textContent": "Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010) Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is not recommended for the treatment of metastatic colorectal cancer.\n\nwww.nice.org.uk/TA212",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p> <p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <b>not</b> recommended for the treatment of metastatic colorectal cancer.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA212\">www.nice.org.uk/TA212</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA263",
                        "label": "www.nice.org.uk/TA263"
                    }
                ],
                "fundingIdentifier": "NICE TA263",
                "textContent": "Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) Bevacizumab in combinations with capecitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.\n\nwww.nice.org.uk/TA263",
                "html": "<p outputclass=\"title\">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</p> <p>Bevacizumab in combinations with capecitabine is <b>not</b> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA263\">www.nice.org.uk/TA263</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76147",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78591",
                "label": "Hormones, malignant disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_923",
                "label": "Capecitabine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76147",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}